A Single Nucleotide Polymorphism in the MDM2 Gene Disrupts the Oscillation of p53 and MDM2 Levels in Cells
Open Access
- 15 March 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (6), 2757-2765
- https://doi.org/10.1158/0008-5472.can-06-2656
Abstract
Oscillations of both p53 and MDM2 proteins have been observed in cells after exposure to stress. A mathematical model describing these oscillations predicted that oscillations occur only at selected levels of p53 and MDM2 proteins. This model prediction suggests that oscillations will disappear in cells containing high levels of MDM2 as observed with a single nucleotide polymorphism in the MDM2 gene (SNP309). The effect of SNP309 upon the p53-MDM2 oscillation was examined in various human cell lines and the oscillations were observed in the cells with at least one wild-type allele for SNP309 (T/T or T/G) but not in cells homozygous for SNP309 (G/G). Furthermore, estrogen preferentially stimulated the transcription of MDM2 from SNP309 G allele and increased the levels of MDM2 protein in estrogen-responsive cells homozygous for SNP309 (G/G). These results suggest the possibility that SNP309 G allele may contribute to gender-specific tumorigenesis through further elevating the MDM2 levels and disrupting the p53-MDM2 oscillation. Furthermore, using the H1299-HW24 cells expressing wild-type p53 under a tetracycline-regulated promoter, the p53-MDM2 oscillation was observed only when p53 levels were in a specific range, and DNA damage was found to be necessary for triggering the p53-MDM2 oscillation. This study shows that higher levels of MDM2 in cells homozygous for SNP309 (G/G) do not permit coordinated p53-MDM2 oscillation after stress, which might contribute to decreased efficiency of the p53 pathway and correlates with a clinical phenotype (i.e., the development of cancers at earlier age of onset in female). [Cancer Res 2007;67(6):2757–65]This publication has 34 references indexed in Scilit:
- Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndromeJournal of Medical Genetics, 2006
- MDM2 promoter variation and age of diagnosis of acute lymphoblastic leukemiaLeukemia, 2005
- The p53 pathway: positive and negative feedback loopsOncogene, 2005
- A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in HumansCell, 2004
- Differential regulation of the human progesterone receptor gene through an estrogen response element half site and Sp1 sitesThe Journal of Steroid Biochemistry and Molecular Biology, 2004
- In vivo characterization of regulatory polymorphisms by allele-specific quantification of RNA polymerase loadingNature Genetics, 2003
- Abnormal expression of MDM-2 in breast carcinomasBreast Cancer Research and Treatment, 1996
- mdm2 gene alterations and mdm2 protein expression in breast carcinomasThe Journal of Pathology, 1995
- Phosphorylation of RNA polymerase II C-terminal domain and transcriptional elongationNature, 1994
- Locus-specific variation in phosphorylation state of RNA polymerase II in vivo: correlations with gene activity and transcript processing.Journal of Bone and Joint Surgery, 1993